These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 27000240)

  • 41. Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
    Tamura S; Warabi Y; Matsubara S
    J Clin Pharm Ther; 2012 Dec; 37(6):724-5. PubMed ID: 22642738
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.
    Lacy M; Hauser M; Pliskin N; Assuras S; Valentine MO; Reder A
    Mult Scler; 2013 Nov; 19(13):1765-72. PubMed ID: 23652214
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trial of interferon-beta in multiple sclerosis stopped early.
    Bonn D
    Lancet; 1998 Feb; 351(9102):573. PubMed ID: 9492786
    [No Abstract]   [Full Text] [Related]  

  • 44. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis.
    Banwell B; Reder AT; Krupp L; Tenembaum S; Eraksoy M; Alexey B; Pohl D; Freedman M; Schelensky L; Antonijevic I
    Neurology; 2006 Feb; 66(4):472-6. PubMed ID: 16505297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
    Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study.
    Chiu AW; Richert N; Ehrmantraut M; Ohayon J; Gupta S; Bomboi G; Gaindh D; Cantor FK; Frank JA; McFarland HF; Bagnato F
    Arch Neurol; 2009 Jan; 66(1):39-43. PubMed ID: 19001157
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interferon beta in multiple sclerosis.
    Gross M
    Lancet; 1999 Aug; 354(9177):512; author reply 512-3. PubMed ID: 10465198
    [No Abstract]   [Full Text] [Related]  

  • 48. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.
    Genç K; Dona DL; Reder AT
    J Clin Invest; 1997 Jun; 99(11):2664-71. PubMed ID: 9169496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interferon beta in multiple sclerosis.
    Napier JC
    Lancet; 1999 Aug; 354(9177):512; author reply 512-3. PubMed ID: 10465197
    [No Abstract]   [Full Text] [Related]  

  • 51. [Profile of efficacy and safety in the treatment of remittent-recurrent multiple sclerosis with interferon beta-1b].
    Río J; Marzo ME; Tintoré M; Borrás C; Montalbán X
    Neurologia; 1998 Nov; 13(9):422-6. PubMed ID: 9883016
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b.
    Wells J; Kossard S; McGrath M
    Australas J Dermatol; 2005 Aug; 46(3):202-4. PubMed ID: 16008658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
    Knobler RL; Greenstein JI; Johnson KP; Lublin FD; Panitch HS; Conway K; Grant-Gorsen SV; Muldoon J; Marcus SG; Wallenberg JC
    J Interferon Res; 1993 Oct; 13(5):333-40. PubMed ID: 8301153
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Current status of interferon beta-1b in multiple sclerosis therapy].
    Hartung HP
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():11-6. PubMed ID: 11603110
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment of relapsing-remitting multiple sclerosis with interferon beta type 1-b].
    Bencsik K; Rajda C; Klivényi P; Járdánházy T; Török M; Vécsei L
    Orv Hetil; 1999 Apr; 140(14):763-6. PubMed ID: 10224846
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.
    Calabresi PA; Tranquill LR; Dambrosia JM; Stone LA; Maloni H; Bash CN; Frank JA; McFarland HF
    Ann Neurol; 1997 May; 41(5):669-74. PubMed ID: 9153530
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interferon causes no myasthenia in a seropositive patient with multiple sclerosis.
    Shimizu H; Kataoka H; Kawahara M; Hirano M; Furiya Y; Ueno S
    Clin Neurol Neurosurg; 2007 Apr; 109(3):277-8. PubMed ID: 17118531
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
    Alping P; Frisell T; Novakova L; Islam-Jakobsson P; Salzer J; Björck A; Axelsson M; Malmeström C; Fink K; Lycke J; Svenningsson A; Piehl F
    Ann Neurol; 2016 Jun; 79(6):950-8. PubMed ID: 27038238
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets.
    Lundy SK; Wu Q; Wang Q; Dowling CA; Taitano SH; Mao G; Mao-Draayer Y
    Neurol Neuroimmunol Neuroinflamm; 2016 Apr; 3(2):e211. PubMed ID: 27006972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate.
    Ma BB; Ostrow LW; Newsome SD
    Neurol Neuroimmunol Neuroinflamm; 2016 Apr; 3(2):e203. PubMed ID: 27027095
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.